Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „described“
Suchtreffer
Begriffe & Kennungen
Capecitabine Accord · 4.8 · Encephalopathy In addition to the ADRs described in tables 4 and 5, and based on the above pooled analysis fro
Eintrag öffnenCapecitabine Teva · 4.8 · In addition to the ADRs described in tables 4 and 5, and based on the above pooled analysis from clinical safe
Eintrag öffnenCapecitabine Teva · 4.8 · In addition to the ADRs described in tables 4 and 5, the following ADRs with an incidence of less than 0.1% we
Eintrag öffnenCellCept · 4.8 · De novo purine synthesis inhibitors associated acute inflammatory syndrome has been described from post-market
Eintrag öffnenCellCept · 4.8 · De novo purine synthesis inhibitors associated acute inflammatory syndrome has been described from post-market
Eintrag öffnenCellCept · 4.8 · De novo purine synthesis inhibitors associated acute inflammatory syndrome has been described from post-market
Eintrag öffnenCellCept · 4.8 · De novo purine synthesis inhibitors associated acute inflammatory syndrome has been described from post-market
Eintrag öffnenCinryze · 4.8 · 6 Local reactions at the injection site were uncommon. In clinical studies local reactions (described as pain,
Eintrag öffnenClopidogrel BGR (previously Zylagren) · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnenClopidogrel HCS · 4.5 · 6 Apart from the specific medicinal product interaction information described above, interaction studies with
Eintrag öffnenClopidogrel Krka d.d. (previously Zopya) · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnenClopidogrel Krka · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnenClopidogrel TAD · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnenClopidogrel Taw Pharma (previously Clopidogrel Mylan) · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnenClopidogrel Teva (hydrogen sulphate) · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnenClopidogrel Zentiva (previously Clopidogrel Winthrop) · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with cl
Eintrag öffnenClopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover) · 4.5 · Apart from the specific medicinal product interaction information described above, interaction studies with Cl
Eintrag öffnenCorlentor · 4.8 · Luminous phenomena (phosphenes) were reported by 14.5% of patients, described as a transient enhanced brightne
Eintrag öffnenDexdor · 4.8 · Clinically significant hypotension or bradycardia should be treated as described in section 4.4.
Eintrag öffnen